Valuation: Renalytix Plc

Market Cap 13.34M 11.66M 10.78M 9.89M 18.72M 1.29B 19.05M 129M 50.51M 628M 50.08M 48.98M 2.17B P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 17.94M 15.68M 14.5M 13.3M 25.18M 1.73B 25.62M 173M 67.93M 844M 67.36M 65.88M 2.91B EV / Sales 2024
11,059,330x
EV / Sales 2025 12,499,418x
Free-Float
73.31%
Yield 2024 *
-
Yield 2025 -
1 day-2.37%
1 week-8.17%
Current month+32.50%
1 month+61.30%
3 months+32.50%
6 months-55.62%
Current year-48.76%
1 week 1.86
Extreme 1.855
2.07
1 month 1.11
Extreme 1.11
2.07
Current year 1
Extreme 0.999
4.3
1 year 1
Extreme 0.999
8.09
3 years 1
Extreme 0.999
91.5
5 years 1
Extreme 0.999
874.5
10 years 1
Extreme 0.999
892.75
Manager TitleAgeSince
Chief Executive Officer 58 2018-03-14
President 65 2024-04-29
Director of Finance/CFO 68 2024-05-27
Director TitleAgeSince
Chairman 62 2024-11-04
Director/Board Member 58 2018-03-14
Chairman 74 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%-8.17% - - 15.32M
-1.11%+1.69%+16.91%-20.02% 17.53B
-3.55%+3.05%+7.19%+95.22% 1.67B
-2.06%-2.03%-32.91%-78.47% 1.24B
-2.16%-6.81%-38.35%+11.21% 1.01B
+1.98%+10.32%-24.47%-50.67% 672M
+2.44%+7.74%-36.04%-54.14% 576M
-0.98%-3.71%+36.05%-53.30% 453M
-1.65%+0.16%-54.38%-58.99% 387M
-3.29%+16.11%+47.89% - 332M
Average -1.19%+2.81%-8.68%-26.14% 2.65B
Weighted average by Cap. -1.11%+4.65%+8.49%-16.57%

Financials

2024 2025
Net sales 2.29 2 1.85 1.7 3.21 220.57 3.27 22.07 8.67 107.71 8.6 8.41 371.86 3 2.62 2.43 2.23 4.21 289.08 4.28 28.92 11.36 141.17 11.27 11.02 487.36
Net income -33.46M -29.24M -27.04M -24.82M -46.97M -3.22B -47.79M -323M -127M -1.57B -126M -123M -5.44B -20.4M -17.83M -16.49M -15.13M -28.64M -1.97B -29.14M -197M -77.26M -960M -76.61M -74.93M -3.31B
Net Debt 3.86M 3.37M 3.12M 2.86M 5.41M 371M 5.51M 37.16M 14.6M 181M 14.48M 14.16M 626M 4.6M 4.02M 3.72M 3.41M 6.46M 443M 6.57M 44.35M 17.42M 216M 17.27M 16.9M 747M
Logo Renalytix Plc
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
46
Date Price Change Volume
26-07-16 US$1.855 -2.37% 1,015
26-07-15 US$1.900 -0.52% 186
26-07-14 US$1.910 -7.51% 6,410
26-07-13 US$2.065 +2.23% 4,133

Annual profits - Rate of surprise